Fluoxetine in the Treatment of Premenstrual Dysphoria
We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiper...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 1997-05, Vol.16 (5), p.346-356 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 356 |
|---|---|
| container_issue | 5 |
| container_start_page | 346 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 16 |
| creator | Su, Tung-Ping Schmidt, Peter J Danaceau, Merry A Tobin, Marie B Rosenstein, Donald L Murphy, Dennis L Rubinow, David R |
| description | We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiperazine (m-CPP) challenge during the follicular and luteal phases of the menstrual cycle. We evaluated the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetine. Compared with baseline, fluoxetine, but not placebo, treatment significantly improved both emotional and physical symptoms. We identified 11 (65%) fluoxetine responders who no longer met diagnostic criteria for PMDD during fluoxetine but remained symptomatic during placebo treatment. In addition, acute symptomatic improvement also occurred following m-CPP administration in 7 of 10 women with PMDD. The small number of m-CPP nonresponders did not respond to fluoxetine either. Our findings confirm that fluoxetine is an effective treatment of PMDD. |
| doi_str_mv | 10.1016/S0893-133X(96)00245-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78960309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78960309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-67a484449c7f14d6c9170b0beb8832c2b73587d199bf1f78421dd44688b620bf3</originalsourceid><addsrcrecordid>eNqNkF1LwzAUhoMoc378hEEvRPSimjRpPi5lOhUGCk7oXUjS1HX0YyYtuH9vtpV5KxzIgfc554QHgAmCdwgiev8BucAxwji7EfQWwoSkcXYExogRGFNMsmMwPiCn4Mz7FYQoZZSPwEggGIqOQTqr-vbHdmVjo7KJuqWNFs6qrrZNF7VF9O5saH3nelVFjxu_XrauVBfgpFCVt5fDew4-Z0-L6Us8f3t-nT7MY0OI6GLKFOEktIYViOTUCMSghtpqznFiEs1wylmOhNAFKhgnCcpzQijnmiZQF_gcXO_3rl373Vvfybr0xlaVamzbe8m4oBBDEcB0DxrXeu9sIdeurJXbSATlVpfc6ZJbF1JQudMlszA3GQ70urb5YWrwE_KrIVfeqKpwqjGlP2AJZUSkOGB0j_mQNF_WyVXbuyao-e_9RnW9s3-_xhymKcW_RB2MWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78960309</pqid></control><display><type>article</type><title>Fluoxetine in the Treatment of Premenstrual Dysphoria</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Su, Tung-Ping ; Schmidt, Peter J ; Danaceau, Merry A ; Tobin, Marie B ; Rosenstein, Donald L ; Murphy, Dennis L ; Rubinow, David R</creator><creatorcontrib>Su, Tung-Ping ; Schmidt, Peter J ; Danaceau, Merry A ; Tobin, Marie B ; Rosenstein, Donald L ; Murphy, Dennis L ; Rubinow, David R</creatorcontrib><description>We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiperazine (m-CPP) challenge during the follicular and luteal phases of the menstrual cycle. We evaluated the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetine. Compared with baseline, fluoxetine, but not placebo, treatment significantly improved both emotional and physical symptoms. We identified 11 (65%) fluoxetine responders who no longer met diagnostic criteria for PMDD during fluoxetine but remained symptomatic during placebo treatment. In addition, acute symptomatic improvement also occurred following m-CPP administration in 7 of 10 women with PMDD. The small number of m-CPP nonresponders did not respond to fluoxetine either. Our findings confirm that fluoxetine is an effective treatment of PMDD.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1016/S0893-133X(96)00245-X</identifier><identifier>PMID: 9109106</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Antidepressive Agents, Second-Generation - therapeutic use ; Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Double-Blind Method ; Female ; Fluoxetine - therapeutic use ; Humans ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neuropharmacology ; Neurosciences ; original-article ; Personality Inventory ; Pharmacology. Drug treatments ; Pharmacotherapy ; Piperazines - pharmacology ; Premenstrual Syndrome - drug therapy ; Prospective Studies ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Self-Assessment ; Serotonin Receptor Agonists - pharmacology</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 1997-05, Vol.16 (5), p.346-356</ispartof><rights>American College of Neuropsychopharmacology 1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-67a484449c7f14d6c9170b0beb8832c2b73587d199bf1f78421dd44688b620bf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1016/S0893-133X(96)00245-X$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1016/S0893-133X(96)00245-X$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2674953$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9109106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Tung-Ping</creatorcontrib><creatorcontrib>Schmidt, Peter J</creatorcontrib><creatorcontrib>Danaceau, Merry A</creatorcontrib><creatorcontrib>Tobin, Marie B</creatorcontrib><creatorcontrib>Rosenstein, Donald L</creatorcontrib><creatorcontrib>Murphy, Dennis L</creatorcontrib><creatorcontrib>Rubinow, David R</creatorcontrib><title>Fluoxetine in the Treatment of Premenstrual Dysphoria</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacol</addtitle><addtitle>Neuropsychopharmacology</addtitle><description>We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiperazine (m-CPP) challenge during the follicular and luteal phases of the menstrual cycle. We evaluated the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetine. Compared with baseline, fluoxetine, but not placebo, treatment significantly improved both emotional and physical symptoms. We identified 11 (65%) fluoxetine responders who no longer met diagnostic criteria for PMDD during fluoxetine but remained symptomatic during placebo treatment. In addition, acute symptomatic improvement also occurred following m-CPP administration in 7 of 10 women with PMDD. The small number of m-CPP nonresponders did not respond to fluoxetine either. Our findings confirm that fluoxetine is an effective treatment of PMDD.</description><subject>Adult</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fluoxetine - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Neurosciences</subject><subject>original-article</subject><subject>Personality Inventory</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacotherapy</subject><subject>Piperazines - pharmacology</subject><subject>Premenstrual Syndrome - drug therapy</subject><subject>Prospective Studies</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Self-Assessment</subject><subject>Serotonin Receptor Agonists - pharmacology</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF1LwzAUhoMoc378hEEvRPSimjRpPi5lOhUGCk7oXUjS1HX0YyYtuH9vtpV5KxzIgfc554QHgAmCdwgiev8BucAxwji7EfQWwoSkcXYExogRGFNMsmMwPiCn4Mz7FYQoZZSPwEggGIqOQTqr-vbHdmVjo7KJuqWNFs6qrrZNF7VF9O5saH3nelVFjxu_XrauVBfgpFCVt5fDew4-Z0-L6Us8f3t-nT7MY0OI6GLKFOEktIYViOTUCMSghtpqznFiEs1wylmOhNAFKhgnCcpzQijnmiZQF_gcXO_3rl373Vvfybr0xlaVamzbe8m4oBBDEcB0DxrXeu9sIdeurJXbSATlVpfc6ZJbF1JQudMlszA3GQ70urb5YWrwE_KrIVfeqKpwqjGlP2AJZUSkOGB0j_mQNF_WyVXbuyao-e_9RnW9s3-_xhymKcW_RB2MWw</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>Su, Tung-Ping</creator><creator>Schmidt, Peter J</creator><creator>Danaceau, Merry A</creator><creator>Tobin, Marie B</creator><creator>Rosenstein, Donald L</creator><creator>Murphy, Dennis L</creator><creator>Rubinow, David R</creator><general>Springer International Publishing</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>Fluoxetine in the Treatment of Premenstrual Dysphoria</title><author>Su, Tung-Ping ; Schmidt, Peter J ; Danaceau, Merry A ; Tobin, Marie B ; Rosenstein, Donald L ; Murphy, Dennis L ; Rubinow, David R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-67a484449c7f14d6c9170b0beb8832c2b73587d199bf1f78421dd44688b620bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fluoxetine - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Neurosciences</topic><topic>original-article</topic><topic>Personality Inventory</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacotherapy</topic><topic>Piperazines - pharmacology</topic><topic>Premenstrual Syndrome - drug therapy</topic><topic>Prospective Studies</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Self-Assessment</topic><topic>Serotonin Receptor Agonists - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Tung-Ping</creatorcontrib><creatorcontrib>Schmidt, Peter J</creatorcontrib><creatorcontrib>Danaceau, Merry A</creatorcontrib><creatorcontrib>Tobin, Marie B</creatorcontrib><creatorcontrib>Rosenstein, Donald L</creatorcontrib><creatorcontrib>Murphy, Dennis L</creatorcontrib><creatorcontrib>Rubinow, David R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Tung-Ping</au><au>Schmidt, Peter J</au><au>Danaceau, Merry A</au><au>Tobin, Marie B</au><au>Rosenstein, Donald L</au><au>Murphy, Dennis L</au><au>Rubinow, David R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fluoxetine in the Treatment of Premenstrual Dysphoria</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><stitle>Neuropsychopharmacol</stitle><addtitle>Neuropsychopharmacology</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>16</volume><issue>5</issue><spage>346</spage><epage>356</epage><pages>346-356</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>We performed a double-blind, placebo-controlled, crossover trial of fluoxetine in 17 women with prospectively confirmed PMS who also met criteria for premenstrual dysphoric disorder (PMDD). A subset of 10 women with PMDD and an additional 10 controls participated in a single-dose m-chlorophenylpiperazine (m-CPP) challenge during the follicular and luteal phases of the menstrual cycle. We evaluated the ability of the acute behavioral response to luteal phase m-CPP administration to predict therapeutic response to fluoxetine. Compared with baseline, fluoxetine, but not placebo, treatment significantly improved both emotional and physical symptoms. We identified 11 (65%) fluoxetine responders who no longer met diagnostic criteria for PMDD during fluoxetine but remained symptomatic during placebo treatment. In addition, acute symptomatic improvement also occurred following m-CPP administration in 7 of 10 women with PMDD. The small number of m-CPP nonresponders did not respond to fluoxetine either. Our findings confirm that fluoxetine is an effective treatment of PMDD.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>9109106</pmid><doi>10.1016/S0893-133X(96)00245-X</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 1997-05, Vol.16 (5), p.346-356 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78960309 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | Adult Antidepressive Agents, Second-Generation - therapeutic use Behavioral Sciences Biological and medical sciences Biological Psychology Double-Blind Method Female Fluoxetine - therapeutic use Humans Medical sciences Medicine Medicine & Public Health Middle Aged Neuropharmacology Neurosciences original-article Personality Inventory Pharmacology. Drug treatments Pharmacotherapy Piperazines - pharmacology Premenstrual Syndrome - drug therapy Prospective Studies Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Self-Assessment Serotonin Receptor Agonists - pharmacology |
| title | Fluoxetine in the Treatment of Premenstrual Dysphoria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A59%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fluoxetine%20in%20the%20Treatment%20of%20Premenstrual%20Dysphoria&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Su,%20Tung-Ping&rft.date=1997-05-01&rft.volume=16&rft.issue=5&rft.spage=346&rft.epage=356&rft.pages=346-356&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1016/S0893-133X(96)00245-X&rft_dat=%3Cproquest_cross%3E78960309%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78960309&rft_id=info:pmid/9109106&rfr_iscdi=true |